IE00B4Q5ZN47 - Common Stock
JAZZ PHARMACEUTICALS PLC
NASDAQ:JAZZ (4/19/2024, 7:00:02 PM)
After market: 110.35 +0.41 (+0.37%)109.94
+0.67 (+0.61%)
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
JAZZ PHARMACEUTICALS PLC
Fifth Fl, Waterloo Exchange, Waterloo Road
DUBLIN DUBLIN D04
P: 35316347800
CEO: Bruce C. Cozadd
Employees: 2800
Website: https://www.jazzpharma.com/
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024,...
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two...
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License...
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on...
Here you can normally see the latest stock twits on JAZZ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: